Gracell Biotechnologies I... (GRCL)
NASDAQ: GRCL
· Real-Time Price · USD
10.25
0.01 (0.05%)
At close: Feb 21, 2024, 10:00 PM
Gracell Biotechnologies Balance Sheet Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 1.68B | -157.98M | 1.27B | 1.45B | 1.43B | 1.54B | 1.62B | 1.83B | 1.95B | 2.05B | 2.16B |
Short-Term Investments | 30.46M | 3.57M | 3.57M | 3.56M | 198.16M | 172.2M | 73.58M | 3.62M | 3.6M | 3.73M | 11.61M |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 7.04M | 10.89M | 11.76M | 15.85M | 18.51M | 3.17M | 27.86M | 1.62M | 22.24M | 13.53M | 19.9M |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.00 | n/a | n/a | n/a |
Inventory | n/a | 1.7K | n/a | -26.33M | n/a | 21.55M | n/a | 8.7M | n/a | n/a | n/a |
Other Current Assets | 66.4M | 53.7M | 47.53M | 37.55M | 40.34M | 24.17M | 66.6M | 46.04M | 60.93M | 62.94M | 54.9M |
Total Current Assets | 1.77B | 1.25B | 1.32B | 1.5B | 1.67B | 1.74B | 1.76B | 1.89B | 2.02B | 2.12B | 2.22B |
Property-Plant & Equipment | 108.67M | 119.59M | 137.06M | 144.67M | 149.91M | 156.7M | 144.08M | 173.44M | 156.15M | 161.68M | 143.81M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 115.7M | 130.48M | 148.82M | 160.52M | 168.42M | 159.87M | 171.94M | 175.06M | 178.39M | 175.21M | 163.71M |
Total Assets | 1.89B | 1.38B | 1.47B | 1.66B | 1.84B | 1.9B | 1.93B | 2.06B | 2.2B | 2.29B | 2.39B |
Account Payables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 62.46M | n/a | n/a | n/a |
Deferred Revenue | n/a | n/a | n/a | 2.9M | n/a | 2.9M | n/a | 2.9M | n/a | n/a | n/a |
Short-Term Debt | 80.45M | 115.48M | 136.53M | 129.99M | 146.8M | 121.56M | 104.97M | 86M | 75.97M | 76.25M | 77.11M |
Other Current Liabilities | 149.02M | 78.34M | 75.07M | 90.65M | 99.74M | 92.64M | 82.15M | 6.66M | 61.31M | 55.62M | 43.91M |
Total Current Liabilities | 229.48M | 193.82M | 211.6M | 220.64M | 246.54M | 217.1M | 187.12M | 155.12M | 137.28M | 131.87M | 121.02M |
Long-Term Debt | 35.37M | 42.5M | 46.09M | 52.99M | 56.98M | 60.51M | 65.92M | 69.18M | 74.44M | 76.93M | 61.52M |
Other Long-Term Liabilities | 4.02M | 4.85M | 5.38M | 6.88M | 7.91M | 7.76M | 7.68M | 8.46M | 9.44M | 10.1M | 11.08M |
Total Long-Term Liabilities | 39.39M | 47.35M | 51.47M | 59.87M | 64.89M | 68.27M | 73.59M | 77.64M | 83.88M | 87.04M | 72.6M |
Total Liabilities | 268.86M | 241.17M | 263.07M | 280.51M | 311.43M | 285.38M | 260.72M | 232.77M | 221.16M | 218.91M | 193.62M |
Total Debt | 115.82M | 157.98M | 182.62M | 182.98M | 203.78M | 182.07M | 170.89M | 155.18M | 150.42M | 153.19M | 138.63M |
Common Stock | 324K | 225K | 223K | 223K | 223K | 223K | 223K | 223K | 223K | 222K | 222K |
Retained Earnings | -1.99B | -1.92B | -1.78B | -1.63B | -1.49B | -1.32B | -1.18B | -1.02B | -889.19M | -759.9M | -663.68M |
Comprehensive Income | 113.94M | 118.09M | 55.65M | 73.53M | 98.71M | 17.66M | -64.37M | -57.94M | -27.71M | -35.05M | -284K |
Shareholders Equity | 1.62B | 1.14B | 1.21B | 1.38B | 1.53B | 1.61B | 1.67B | 1.83B | 1.98B | 2.07B | 2.19B |
Total Investments | 30.46M | 3.57M | 3.57M | 3.56M | 198.16M | 172.2M | 73.58M | 3.62M | 3.6M | 3.73M | 11.61M |